In 2025, Novo Nordisk submitted Orforglipron for regulatory review by the FDA, but it is not yet approved
We thank the Shanghai Municipal Government, ShanghaiTech University and GPCR Consortium for financial support
Research since 2023 has shown improvements in ovulation and menstrual regularity for some patients using GLP-1s (Escobar-Morreale et al., 2024)
By combining physician-led protocols, customized formulations, and direct-to-door delivery, MEDVi removes logistical and cost barriers traditionally associated with advanced weight loss treatments
How Oral Semaglutide Affects Levothyroxine Absorption A pharmacokinetic study specifically examined the interaction between oral semaglutide (Rybelsus) and levothyroxine
Genetic differences in GLP-1 receptor sensitivity and remaining beta cell function significantly affect individual treatment response